drugset
drugset / Trial / NCT01632150

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT01632150 ↗

Phase 2 Completed 51 enrolled Bristol-Myers Squibb AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.

Timeline

Start
2012-05
Primary completion
2013-10
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Elotuzumab Monoclonal antibody 400 mg Intravenous
Background Cyclophosphamide Other / unclassified 50 mg Oral
Background Dexamethasone Small molecule 2 mg Oral
Background Dexamethasone Small molecule 4 mg Oral
Background Dexamethasone Small molecule 4 mg/ml Oral
Background Dexamethasone Small molecule 8 mg/ml Oral
Background Thalidomide Other / unclassified 50 mg Oral

Indications

refractory plasma cell neoplasm